Merck & Company, Inc. (NYSE:MRK) posted its quarterly earnings data on Friday. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08, Bloomberg Earnings reports. The company had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. Merck &’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.07 earnings per share. Merck & updated its FY17 guidance to $3.91-3.97 EPS.
Merck & (MRK) traded down 6.05% during midday trading on Friday, hitting $58.24. The stock had a trading volume of 29,561,260 shares. The firm has a 50-day moving average of $64.26 and a 200-day moving average of $63.65. The company has a market cap of $158.84 billion, a PE ratio of 31.53 and a beta of 0.80. Merck & has a 12-month low of $57.82 and a 12-month high of $66.80.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fort Washington Investment Advisors Inc. OH lifted its stake in Merck & by 133.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after purchasing an additional 82,454 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Merck & by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after acquiring an additional 107,201 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its position in shares of Merck & by 41.9% during the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after acquiring an additional 87,443 shares during the period. Stevens Capital Management LP purchased a new stake in shares of Merck & during the first quarter worth $15,126,000. Finally, Trust Co increased its position in shares of Merck & by 2.8% during the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after acquiring an additional 1,852 shares during the period. Hedge funds and other institutional investors own 72.86% of the company’s stock.
A number of brokerages have commented on MRK. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. BMO Capital Markets set a $70.00 price target on Merck & and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Credit Suisse Group restated an “outperform” rating and issued a $74.00 price target (down previously from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Finally, Cowen and Company restated a “hold” rating and issued a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. Merck & currently has an average rating of “Hold” and an average target price of $70.00.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.